Masimo ORitm Granted De Novo as the First and Only FDA-Cleared Noninvasive and Continuous Parameter to Provide Insight into Hyperoxia Under Supplemental Oxygen
Le Lézard,
Masimo (NASDAQ: MASI) today announced that ORitm, a noninvasive, continuous parameter designed to provide additional insight…